Results 171 to 180 of about 15,263 (254)

Cutaneous lymphomas reported following the use of dupilumab, nemolizumab, tralokinumab, or lebrikizumab: A case investigation based on JADER database and disproportionality analysis. [PDF]

Intractable Rare Dis Res
Tanaka H, Ishii T.
europepmc   +1 more source

Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In adults with moderate AD post‐TCS and ‐TCI, who may otherwise be eligible for systemic therapy, 1.5% ruxolitinib cream improved clinical signs and symptoms in the TRuE‐AD4 study. Abstract Background In patients with moderate atopic dermatitis (AD), topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) often do not sufficiently ...
José Manuel Carrascosa, Vimal H. Prajapati, H. Chih‐ho Hong, Viktoria Eleftheriadou, Athanasios Tsianakas, Alexander A. Navarini, Ketty Peris, Eingun James Song, Raj Chovatiya, Sébastien Barbarot, Konstantin Popovic, Haq Nawaz, Qian Li, Vivek Purohit, Andreas Wollenberg   +14 more
wiley   +1 more source

Dupilumab enables glucocorticoid withdrawal in refractory multisite mucous membrane pemphigoid: a case report. [PDF]

Front Med (Lausanne)
Hu Y, Xu LL, Li KH, Yu CS, Wang SB.
europepmc   +1 more source

Management of chronic urticaria: Current status and future prospect

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Chronic urticaria is driven by mast cell activation through autoimmune, inflammatory, and neuroimmune pathways. A structured approach combining diagnosis, patient‐reported outcomes, stepwise therapy, treatment optimization, monitoring and emerging targeted agents may improve disease control and enable more personalized management.
Andaç Salman, Mona Al‐Ahmad, Maryam Al‐Nesf, Chia‐Yu Chu, Luis Felipe Ensina, Ana M. Gimenez‐Arnau, Margarida Gonçalo, Clive Grattan, Michihiro Hide, Pavel Kolkhir, Martin Metz, Iman Nasr, Romi Saini, Simon Francis Thomsen, Torsten Zuberbier, Emek Kocaturk   +15 more
wiley   +1 more source

Summary of Research: Dupilumab Safety for Treating Infants to Adults with Moderate-to-Severe Atopic Dermatitis. [PDF]

Adv Ther
Langley RG, Gherardi G, Coleman A, Ardeleanu M, Rodríguez-Marco A, Levy S, Bansal A, Chen Z, Rossi AB, Shumel B, Khokhar FA.   +10 more
europepmc   +1 more source

Regional Nerve Blocks and OnabotulinumtoxinA in the Management of Trigeminal Trophic Syndrome: A Case Report of a Novel Multimodal Approach

Oral Surgery, EarlyView.
ABSTRACT Objective Trigeminal trophic syndrome (TTS) is a rare condition caused by trigeminal nerve injury, classically characterized by anaesthesia, paresthesia and facial ulceration. We present two cases of TTS successfully managed with regional nerve blocks and onabotulinumtoxinA. Methods Two patients—a 54‐year‐old woman and a 65‐year‐old man—with a
Shamin Masrour, Rhea Sudhakaran
wiley   +1 more source

Improvement of Depressive and Fatigue Symptoms under Dupilumab Therapy in Atopic Dermatitis Patients: Results from the TREATgermany Registry. [PDF]

Acta Derm Venereol
Traidl S, Cornelius A, Heinrich L, Siegels D, Zacharias H, Heratizadeh A, Honstein T, Kind B, Stölzl D, Augustin M, Schaefer T, Bong A, Abraham S, Pinter A, Ramaker-Brunke J, Schulz-Kiesow M, Quist S, Schwarz B, Biedermann T, Asefi M, Mann C, Adler N, Sticherling M, Schäkel K, Herrmann A, Meinhardt K, Stahl M, Handrick C, Anders S, Weidinger S, Schmitt J, Werfel T, TREATgermany study group.   +32 more
europepmc   +1 more source

Dupilumab‐Induced Psoriasis in an Adolescent With Severe Atopic Dermatitis: Successful Management With Abrocitinib

Pediatric Dermatology, EarlyView.
ABSTRACT Psoriasiform eruptions have been described in patients treated with dupilumab. This case report describes an adolescent with severe atopic dermatitis who developed a widespread psoriasiform dermatitis 8 months after starting dupilumab. His therapy was switched to abrocitinib resulting in near‐complete resolution of the psoriatic lesions with ...
Grigorios Theodosiou, Åke Svensson
wiley   +1 more source

Cutaneous T-cell lymphoma and dupilumab for atopic dermatitis: Practical guidance for a clinical conundrum. [PDF]

J Eur Acad Dermatol Venereol
De Benedetto A, Mannava KA.
europepmc   +1 more source

Growth Assessment in Children Under 12 Years With Moderate‐to‐Severe Atopic Dermatitis Included in the PEDISTAD Observational Registry

Pediatric Dermatology, EarlyView.
ABSTRACT Background/Objective The multifactorial disease burden of moderate‐to‐severe atopic dermatitis (AD) may affect children's growth. We report height, weight, and body mass index (BMI) of children under 12 years old with moderate‐to‐severe AD in comparison to the general population.
Amy S. Paller, Alan D. Irvine, Eulalia Baselga, Marlies de Graaf, Elaine C. Siegfried, Michael J. Cork, Michele Ramien, Lawrence F. Eichenfield, Bryan Adams, Rajan Gupta, Marius Ardeleanu, Annie Zhang   +11 more
wiley   +1 more source